ASTH · Astrana Health Inc.

The thesis

Astrana Health's recovery case still rests on full-year guidance the company has not changed since the 17 September 2026 short-seller report and the 23 September 2026 cyber disclosure. The Q3 2026 report, due after the close on 5 November 2026, settles it. It has to show revenue of at least $1.000 billion and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of at least $72.5 million, the minimums the company set on 6 August 2026.

The shares closed at $36.94 on 27 October 2026, in split- and dividend-adjusted daily closes. That is below the $37.72 close of 14 October 2026 and above the $34.91 close of 1 October 2026. The 14-day relative strength index (RSI) is 49.1, down from 64.9 on 14 October 2026. The three-month price change is 0.7%, and the close sits 25.8% below the $49.81 52-week high.

The narrative is maturing and still contested: the guidance is well known, and company news shows no new headline since 23 September 2026 that answers the short-report questions. The rebound has faded to a middle reading, and the Q3 report is the next event that can change the case. The rating stays where it was.

Bullish and bearish views on Astrana Health Inc.

The bull case on Astrana Health Inc. (ASTH), in brief: Full-year guidance repeated after both shocks. The bear case: Short-seller questions remain unanswered.

Bull case

• Full-year guidance repeated after both shocks. The investor presentation filed on 23 September 2026 (Exhibit 99.1 to Form 8-K) kept FY2026 revenue at $3.800–4.100 billion and adjusted EBITDA at $255–280 million. Benzinga reported the revenue range against a $4.004 billion analyst estimate.
• Cash generation supports the earnings figures. Astrana reported operating cash flow of $100.8 million and free cash flow of $92.9 million for the six months ended 30 June 2026. Its full-year free cash flow guidance is $105–132.5 million.
• Sell-side targets sit well above the price. Oppenheimer started coverage on 15 September 2026 with an Outperform rating and a $53 target. Freedom Capital Markets kept its Buy rating and $50 target on 1 October 2026, according to GuruFocus.
• Care-delivery network keeps widening. On 12 October 2026 a news report said Verda Healthcare is partnering with AstranaCare Partners of Arizona and Texas on Medicare Advantage care for underserved communities. No financial terms were reported.

Bear case

• Short-seller questions remain unanswered. On 17 September 2026 Glass House Research, which disclosed a short position, questioned Astrana's reserves, acquisition accounting, receivables and adjusted earnings. Company news shows no restatement or auditor statement since then.
• Cyber incident costs not yet measured. The 23 September 2026 Form 8-K, Item 1.05, called the unauthorized data-access incident material. It said the company did not expect a material financial impact. Regulatory and litigation costs at health-care providers can surface well after a first filing.
• Debt is high after the Prospect deal. Long-term debt, net, was $882.7 million against $400.8 million of cash at 30 June 2026, after the Prospect Health acquisition.
• The short report targets that gap.

Price setup

The shares closed at $36.94 on 27 October 2026. The range since the prior note runs from the $34.91 close on 1 October 2026 to the $37.72 close on 14 October 2026. The RSI has dropped from 64.9 to 49.1 over the same fortnight, so the short-lived rally has given back momentum without breaking the low.

The $34 level, just under the 1 October 2026 close, is the lowest recent close the shares must hold on a weekly basis for the recovery case to stand. The 52-week high of $49.81 is 25.8% above the last close, and no close has approached it since the September reports.

Crowding evidence is limited to two items. A named short seller disclosed a position on 17 September 2026, and the Q3 report is nine days away. No insider selling beyond the mechanical tax-withholding filings tied to the CEO's restricted stock vesting is cited here, and no share issuance is reported.

Catalysts, next 30 days

• Q3 reports from large Medicare Advantage insurers, through early November (dates not confirmed here): Medical-cost commentary from insurers shapes how the market reads risk-bearing providers such as Astrana.

Elapsed catalysts

• 5 November 2026: Q3 2026 results after the market close, conference call at 2:30 p.m. PT. The report tests the $1.000 billion revenue and $72.5 million adjusted EBITDA minimums, whether the $255–280 million full-year range holds, and whether management addresses the 17 September 2026 accounting questions. (passed 1d ago)

What would change the view

The recovery case breaks if Q3 revenue falls below $1.000 billion together with a cut to the FY2026 adjusted EBITDA range of $255–280 million. A restatement, a delayed periodic filing or an adverse auditor finding on the practices named in the 17 September 2026 report would also break it. A later filing that reports a material financial impact or regulatory action from the 23 September 2026 cyber incident would weaken it further.

On price, a weekly close below $34, just under the 1 October 2026 close of $34.91, ends the case. The case strengthens if the Q3 report meets both minimums, repeats the full-year ranges and answers the short-report points with specifics.

What it trades with

Astrana trades with other risk-bearing physician groups and Medicare Advantage-linked providers, where medical-cost trends drive margins. Large Medicare Advantage insurers' Q3 commentary on utilization feeds into it. The short-seller dispute and the cyber incident are company-specific and have moved the shares apart from that group since 17 September 2026.